CSL (ASX: CSL), an Australia-based global biotechnology company, announced on Tuesday that it has received approval from the US Food and Drug Administration (FDA) for its HEMGENIX (etranacogene dezaparvovec-drlb), the first and only one-time gene therapy intended to treat appropriate adults with haemophilia B.
The product is approved for the treatment of adults with haemophilia B who presently use factor IX prophylaxis therapy, or have present or historical life-threatening haemorrhage or have repeated, serious spontaneous bleeding episodes. The company said that during the ongoing clinical trial, the product decreased the rate of annual bleeds and 94% of the subjects discontinued factor IX prophylaxis and remained prophylaxis-free.
The approval is supported by outcomes from the ongoing HOPE-B trial. Outcomes from the study revealed that the product enabled patients to produce mean factor IX activity of 39% at six months and 36.7% at 24 months post infusion.
uniQure (Nasdaq: QURE) headed the multi-year clinical development program for HEMGENIX and sponsorship of the clinical trials moved to CSL subsequent to the acquisition of the global rights to commercialise the treatment.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT